Okuwa (OTC:OWWAF) Stock, Quote.Headers.trade-ideas

Okuwa Co Ltd operates a retail chain of stores in Japan. The company's products that it sells include foods, alcoholic beverages, rice, household items, residential goods, upholstery, Do It Yourself products, leisure goods, sporting goods, household appliances, cosmetics, pharmaceuticals, clothing and various other items. It operates more than 15 stores in Wakayama, Osaka, Nara, Mie, Hyogo, Aichi, Gifu, Shizuoka cities in Japan.

OKUWA CO LTD ORD by Okuwa Company Ltd. Wakayama

Okuwa Co Ltd

Capgemini, Confluent, IBM, QuantumBlack, AI by McKinsey, and Unstructured join the MongoDB AI Applications Program (MAAP) ecosystem to help organizations make an impact with AI
MongoDB, Meta collaborating to support developers with Meta models and the end-to-end MAAP technology stack
Leading autism and intellectual and developmental disability software provider CentralReach using MAAP to improve AI-powered care platform
MAAP expansion follows the introduction of vector quantization to MongoDB Atlas Vector Search and recent AI partner integrations
LAS VEGAS, Dec. 2, 2024 /PRNewswire/ -- MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) today at AWS re:Invent announced that a new cohort of organizations have joined the MongoDB AI Applications Program (MAAP) ecosystem of leading AI and tech companies. By lending their experience and expertise to MAAP, Capgemini, Confluent, IBM, QuantumBlack, AI by McKinsey, and Unstructured will offer customers additional integration and solution options, boosting the value customers receive from MAAP. Since it was launched earlier this year, MAAP has already made an impact, helping customers like CentralReach—which provides an AI-powered autism care and intellectual and developmental disabilities (IDD) platform—innovate with AI. The MAAP Center of Excellence Team, a cross-functional group of AI experts at MongoDB, has collaborated with partners and customers across industries to overcome an array of technical challenges, empowering organizations of all sizes to build and deploy AI applications. The expansion of the MongoDB AI Applications Program follows the introduction of vector quantization to MongoDB Atlas Vector Search (which reduces vector sizes while preserving performance—at lower cost), as well as new integrations with leading AI and technology companies.

News

MongoDB Announces Expansion Of The MongoDB AI Applications Program; MongoDB, Meta Collaborating To Support Developers With Meta Models And The End-To-End MAAP Technology Stack

Leading Domestic Manufacturer and Brewer Continues Ongoing Investments in its Communities, Building on $2 Billion Spend Over Last 5 Years 
JACKSONVILLE, Fla., Dec. 2, 2024 /PRNewswire/ --&nbsp;Anheuser-Busch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>), a leading domestic manufacturer and brewer of Michelob ULTRA, Busch Light, Budweiser, and Bud Light, today announced a new $10 million investment in its Jacksonville brewery. Over the last 5 years, Anheuser-Busch has invested nearly $2 billion in its facilities across the country to help create and sustain jobs and drive economic prosperity in the communities where it operates and its employees call home. 
 &nbsp;

Anheuser-Busch Announces A New $10M Investment In Its Jacksonville Brewery

In the high-pressure, constantly evolving world of Silicon Valley, some of the most influential leaders have turned to <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a> in their search for creativity, personal growth and mental clarity. As Business Insider <a href="https://www.businessinsider.com/ceos-founders-who-used-psychedelics-lsd-acid-magic-mushrooms">reported</a>, from Apple's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPL#NASDAQ">APPL</a>) visionary co-founder Steve Jobs to <a href="https://www.benzinga.com/topic/openai">OpenAI</a> CEO Sam Altman, and even Tesla's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Elon Musk, the use of mind-altering substances has played a significant, if often private, role in the development of the tech industry's most powerful figures.
<h3 class="wp-block-heading">Steve Jobs: A &#8220;Profound Experience&#8221; In The Pursuit Of Purpose</h3>
The late Steve Jobs, widely celebrated for his role in revolutionizing technology, was outspoken about how his experiences with <a href="https://www.benzinga.com/topic/lsd">LSD</a> shaped his worldview. Jobs spent his early 20s exploring the boundaries of consciousness through meditation, travel and psychedelics. His exploration of LSD, he later revealed, helped him discover a deeper sense of purpose that would define his career.
&#8220;I came of age at a magical time,&#8221; Jobs told his biographer Walter Isaacson, describing the counterculture of the 1960s and early &#8217;70s. The entrepreneur went on to call his use of LSD "one of the most important things in my life," emphasizing that it had been a profound experience. &#8220;It reinforced my sense of what was important—creating great things instead of making money, putting things back into the stream of history and of human consciousness as much as I could,&#8221; he said.
During a two-year period between 1972 and 1974, Jobs reportedly took LSD between 10 to 15 times, before ultimately stepping away from the drug. His time with psychedelics is often viewed as foundational to his radical thinking and his ability to see beyond the conventional constraints of business.
<h3 class="wp-block-heading">Sam Altman: From Anxiety To Calm Through Psychedelic Retreats</h3>
Sam Altman, the CEO of OpenAI, has been vocal about how psychedelics helped him transform his mental and emotional state. In a September <a href="https://podcasts.apple.com/us/podcast/openais-sam-altman-the-human-behind-the-machine/id1749122105?i=1000670496921">appearanc</a>e on the &#8220;Life in Seven Songs&#8221; podcast, Altman shared how a retreat in Mexico, where psychedelics were used under the guidance of a facilitator, profoundly altered his perception of self and the world.
"If you had told me that, like, one weekend-long retreat in Mexico was going to significantly change that, I would have said absolutely not," Altman said. &#8220;And it really did.&#8221; He revealed that prior to his psychedelic experiences, he had been &#8220;a very anxious, unhappy person,&#8221; but after the retreat, he felt a lasting calm that had not been achieved through other means.
Altman's personal experiences with psychedelics have led him to become an <a href="https://www.benzinga.com/markets/cannabis/24/09/41032240/sam-altmans-psychedelic-breakthrough-how-the-openai-visionary-plans-to-transform-mental-health-c">advocate for their therapeutic potential</a>. The OpenAI co-founder has invested in several startups focusing on psychedelic research and is the board chairman of <a href="https://www.benzinga.com/markets/cannabis/23/04/31964301/can-ai-foster-research-and-psychedelics-therapy-without-replacing-human-connection">Journey Colab</a>, a company working on <a href="http://v">clinical treatments for addiction using psychedelic substances</a>.
<h3 class="wp-block-heading">Sergey Brin: The Quiet Advocate Of Psilocybin</h3>
Google (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) co-founder <a href="https://www.benzinga.com/topic/sergey-brin">Sergey Brin</a>'s relationship with psychedelics has remained largely under the radar. While Brin has not publicly confirmed his use of <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> (the active compound in magic mushrooms), <a href="https://www.wsj.com/articles/silicon-valley-microdosing-ketamine-lsd-magic-mushrooms-d381e214">reports</a> from The Wall Street Journal suggest that he has experimented with the substance. Brin has also demonstrated a keen interest in the therapeutic potential of psychedelics, backing a nonprofit venture, Catalyst4, which has <a href="https://www.benzinga.com/markets/cannabis/24/07/39894676/google-co-founder-sergey-brin-pledges-15m-to-psychedelics-research-start-up">committed $15 million to research</a> a hallucinogenic treatment for mental health conditions.
Brin's participation in <a href="https://www.benzinga.com/markets/cannabis/24/08/40558705/heading-to-burning-man-be-careful-with-your-weed-even-though-its-legal-in-nevada-heres-why">Burning Man</a>, the annual festival known for its exploration of art, community and altered states, suggests that his curiosity about psychedelics could be more than just a passing interest. His connection to psychedelic culture reflects a broader trend among Silicon Valley elites who embrace altered states of consciousness as part of their personal and professional journeys.
<h3 class="wp-block-heading">Elon Musk: &#8216;Mild Exploratory Journeys&#8217; And Ketamine</h3>
Perhaps the most enigmatic of these tech giants when it comes to psychedelic use is Elon Musk. Although Musk has not publicly confirmed any direct use of substances like LSD or magic mushrooms, reports from sources close to him suggest that he has experimented with psychedelics in the past. The Tesla and <a href="https://www.benzinga.com/topic/spacex">SpaceX</a> CEO has <a href="https://www.benzinga.com/general/biotech/24/03/37797951/elon-musk-on-ketamine-and-investors-value-if-there-is-something-im-taking-i-should-keep-taking-it">spoken openly about his use of ketamine</a>, a dissociative anesthetic with hallucinogenic properties, which he says he uses to combat negative emotional states, such as depression.
In an <a href="https://www.youtube.com/watch?v=hhsfjBpKiTw">interview</a> with CNN&#8217;s Don Lemon, Musk revealed that he uses a &#8220;small amount&#8221; of ketamine about once every other week. He suggested that the substance helps him maintain focus during challenging times, particularly when he feels his mental state deteriorating. &#8220;If you use too much ketamine, you can&#8217;t really get work done, and I have a lot of work,&#8221; Musk explained. Despite its recreational use, Musk sees ketamine as a more effective alternative to traditional antidepressants like SSRIs.
Though Musk's public remarks on psychedelics are rare, his willingness to discuss the benefits of the substances, along with his presence at Burning Man, suggest that he sees some value in exploring altered states of consciousness.
<h3 class="wp-block-heading">A Culture Of Exploration In Silicon Valley</h3>
These figures' relationships with psychedelics reflect a larger cultural phenomenon within Silicon Valley, where boundaries are continually being pushed and unconventional methods are sought to enhance creativity and problem-solving. The use of psychedelics is increasingly being viewed not only as a tool for personal exploration but also as a potential therapeutic solution for mental health challenges that often accompany the high-pressure environment of the tech world. Despite the stigma that still surrounds psychedelics in some circles, a <a href="https://www.benzinga.com/topic/psychedelics-research">growing body of research</a> suggests that these substances can play a role in treating everything from depression to addiction, spurring more Silicon Valley leaders to speak out or invest in related startups.
Cover images Shutterstock / Wikimedia

Cannabis

Psychedelics

Media

APPL

GOOG

TSLA

Silicon Valley Titans And Their Psychedelic Journeys: The Experiences That Shaped Them

Shares of Ero Copper Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) were <a href="https://www.benzinga.com/quote/ERO">climbing in early trading on Monday</a>.
The Tucumã project ramp-up and lower average unit costs could enable the company to drive "the strongest production and EBITDA growth in our coverage, according to Goldman Sachs.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/63172fdcdaaf0c0001283ce1/marcio-farid">Analyst Marcio Farid</a> initiated coverage of with a Buy rating and price target of $19.
The Vancouver-based company could generate production and EBITDA growth of 97% and 140% in 2025 and of 112% and 190% in 2026, respectively, Farid said in the initiation note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
In an environment in which copper growth is becoming "more scarce and expensive," Ero seems poised to benefit from "low cost production growth with light capital (JV approach) and relatively low risk," he added.
"Ero Copper is well positioned to benefit from increasing investor preference for pure copper players, especially now that it has delivered on its key Tucumã project, bringing more scale and improving risk perception," the analyst further wrote.
ERO Price Action: Ero shares had risen by 0.53% to $15.30 at the time of publication on Monday.
Read More: <a href="https://www.benzinga.com/news/earnings/24/09/41063013/ero-copper-stock-jumps-5-2-will-it-continue-to-soar">This Copper Company&#8217;s Stock Jumps 5.2%: Will It Continue to Soar?</a>
Image: Shutterstock

Commodities

Ero Copper To Drive 'Strongest Production, EBITDA Growth': Analyst

Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) stock is trading lower on Monday. The company announced that its CEO, Carlos Tavares, <a href="https://www.benzinga.com/news/management/24/12/42258470/jeep-marker-stellantis-ceo-carlos-tavares-resigns-amid-falling-us-sales-and-trade-pressures-board-cites-different-views">has resigned.</a> 
What To Know: The company has established a new Interim Executive Committee, chaired by John Elkann, who is also the Chairman of the Board, to temporarily oversee leadership responsibilities until a permanent CEO is appointed.
&#8220;Our thanks go to Carlos for his years of dedicated service and the role he has played in the creation of Stellantis, in addition to the previous turnarounds of PSA and Opel, setting us on the path to becoming a global leader in our industry,&#8221; said Elkann.
&#8220;I look forward to working with our new Interim Executive Committee, supported by all our Stellantis colleagues, as we complete the process of appointing our new CEO. Together we will ensure the continued deployment of the Company&#8217;s strategy in the long-term interests of Stellantis and all of its stakeholders.&#8221;
Stellantis expects to appoint a new permanent CEO during the first half of 2025. The search process is already underway and will be overseen by a Special Committee of the Board.
The company confirmed its guidance from the end of October for the 2024 fiscal year.
Related Link: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42264100/ethereum-etf-with-integrated-staking-to-be-approved-in-the-future-bernstein">Ethereum ETF With Integrated Staking To Be Approved In The Future: Bernstein</a>
STLA Price Action: At the time of publication, Stellantis stock is trading 7.12% lower at $12.26, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Shutterstock

Movers

STLA

What's Going On With Stellantis Stock Monday?

WIIM

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

Sunrise New Energy shares are trading lower. The company reported October 2024 sales volume.

According to research published in JAMA Network Open, the use of anti-obesity medications, including glucagon-like peptide-1 receptor agonists, was associated with lower incidence and recurrence <a href="https://www.benzinga.com/topic/weight-loss">of alcohol use disorder.</a>
The study analyzed data from 14,053 eligible participants if they started using an anti-obesity medication between January 2022 and August 2023 and refilled the same medication during October or November 2023.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42192091/biden-proposes-medicare-medicaid-access-for-popular-weight-loss-drugs" rel="noreferrer noopener">Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs</a>
The medications were grouped into categories:
<ul>
<li>Metformin, bupropion, and naltrexone.</li>
<li>First-generation GLP-1 receptor agonists, including Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Victoza (liraglutide) and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Trulicity (dulaglutide)</li>
<li>Second-generation GLP-1 receptor agonists, including Eli Lilly&#8217;s Zepbound (tirzepatide) and Novo Nordisk&#8217;s Wegovy (semaglutide)</li>
</ul>
A new cohort <a target="_blank" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2827069" rel="noreferrer noopener">study</a> highlights a notable trend among participants in weight loss programs: a significant portion of individuals reduced their alcohol consumption after starting anti-obesity medications.
The findings suggest potential links between these medications and changes in alcohol use, with various factors influencing this behavior.
Among participants reporting alcohol use at baseline, nearly half (45.3%) reduced their alcohol consumption after beginning the weight loss treatment.
Meanwhile, 52.4% reported no change, and 2.3% noted an increase.
Participants with higher levels of obesity or heavier drinking habits at the start of the study were more likely to reduce alcohol consumption.
Those prescribed Wegovy or Zepbound or the combination of bupropion and naltrexone also showed a tendency to drink less. However, the association with bupropion and naltrexone became statistically insignificant when adjusted for weight loss.
Researchers hypothesized that certain pharmacological properties of obesity drugs might influence alcohol use.
For example, naltrexone reduces alcohol cravings, while GLP-1 RAs may diminish the rewarding effects of both alcohol and food. The study also noted that participants using metformin reported reduced alcohol consumption, possibly due to behavioral strategies emphasizing calorie reduction and the role of alcohol in impairing cognitive restraint.
The researchers acknowledged that the motivation to adopt healthier behaviors could be higher in individuals engaged in structured weight loss programs than those not seeking treatment.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42267027/why-is-purple-biotech-stock-trading-higher-on-monday" target="_blank" rel="noreferrer noopener">Why Is Purple Biotech Stock Trading Higher On Monday?</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study

Arthur J. Gallagher & Co. Acquires Australia-Based Hann Insurance Brokers; Financial Terms Not Disclosed

During the last three months, 5 analysts shared their evaluations of Stitch Fix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $3.86, a high estimate of $5.00, and a low estimate of $2.80. This current average represents a 2.53% decrease from the previous average price target of $3.96. 
<img src="https://www.benzinga.com/files/images/story/2024/1733155260_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Stitch Fix. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$5.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>Joseph Parkhill</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.80</td>
<td>$3.80</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$3.50</td>
<td>$4.50</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stitch Fix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Stitch Fix compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Stitch Fix's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Stitch Fix's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SFIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Stitch Fix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Stitch Fix Better</h2>
Stitch Fix Inc offers personal style services for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandise with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types, and price points including Women's, Petite, Maternity, Men's, and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry, and handbags and sells merchandise across various ranges of price points.
<h3>Financial Insights: Stitch Fix</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: Stitch Fix's revenue growth over 3 months faced difficulties. As of 31 July, 2024, the company experienced a decline of approximately -12.39%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Stitch Fix's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -11.42%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Stitch Fix's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -18.44%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Stitch Fix's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.63.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

SFIX

Analyst Scoreboard: 5 Ratings For Stitch Fix

5 analysts have shared their evaluations of IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $498.2, a high estimate of $575.00, and a low estimate of $435.00. A 10.64% drop is evident in the current average compared to the previous average price target of $557.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733155251_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of IDEXX Laboratories by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Clark</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$500.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$435.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$481.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$575.00</td>
<td>$630.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$500.00</td>
<td>$510.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IDEXX Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IDEXX Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into IDEXX Laboratories's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IDXX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IDEXX Laboratories analyst ratings.</a>
<h2>About IDEXX Laboratories</h2>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>Key Indicators: IDEXX Laboratories's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining IDEXX Laboratories's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.56% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: IDEXX Laboratories's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 23.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): IDEXX Laboratories's ROE excels beyond industry benchmarks, reaching 14.56%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): IDEXX Laboratories's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.88%, the company showcases efficient use of assets and strong financial health.
Debt Management: IDEXX Laboratories's debt-to-equity ratio surpasses industry norms, standing at 0.62. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IDXX

A Glimpse Into The Expert Outlook On IDEXX Laboratories Through 5 Analysts

MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $377.5, along with a high estimate of $425.00 and a low estimate of $340.00. Observing a 18.9% increase, the current average has risen from the previous average price target of $317.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733155241_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of MongoDB by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$425.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$345.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$340.00</td>
<td>$330.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MongoDB. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MongoDB compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of MongoDB's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MongoDB's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MongoDB analyst ratings.</a>
<h2>Get to Know MongoDB Better</h2>
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
<h3>Financial Insights: MongoDB</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: MongoDB's revenue growth over a period of 3 months has been noteworthy. As of 31 July, 2024, the company achieved a revenue growth rate of approximately 12.82%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -11.41%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): MongoDB's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -4.14%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.77%, the company showcases effective utilization of assets.
Debt Management: MongoDB's debt-to-equity ratio is below the industry average. With a ratio of 0.87, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 4 Analyst Recommendations For MongoDB

Wells Fargo analyst Chris Carey maintains Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) with a Overweight and lowers the price target from $78 to $75.

Price Target

Wells Fargo Maintains Overweight on Coca-Cola, Lowers Price Target to $75

Ratings for Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">11</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $398.89, a high estimate of $445.00, and a low estimate of $370.00. Marking an increase of 5.68%, the current average surpasses the previous average price target of $377.44. 
<img src="https://www.benzinga.com/files/images/story/2024/1733155231_0_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Stryker by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$445.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$411.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$418.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$394.00</td>
<td>$383.00</td>
</tr>
<tr>
<td>Kyle Rose</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$386.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$380.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$384.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$381.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$370.00</td>
<td>$366.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$405.00</td>
<td>$378.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$409.00</td>
<td>$393.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$383.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$370.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$405.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Stryker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Stryker compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Stryker's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Stryker's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SYK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Stryker analyst ratings.</a>
<h2>About Stryker</h2>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>A Deep Dive into Stryker's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Stryker's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.92%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Stryker's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 15.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.18%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Stryker's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.01%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 0.77, Stryker faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Stryker

Financial giants have made a conspicuous bearish move on Taiwan Semiconductor. Our analysis of options history for Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) revealed 41 unusual trades.
Delving into the details, we found 39% of traders were bullish, while 48% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $485,502, and 31 were calls, valued at $3,296,628.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $105.0 and $210.0 for Taiwan Semiconductor, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Taiwan Semiconductor's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Taiwan Semiconductor's whale trades within a strike price range from $105.0 to $210.0 in the last 30 days. 
<h3>Taiwan Semiconductor 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733155231_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$14.55</td>
<td>$14.5</td>
<td>$14.46</td>
<td>$185.00</td>
<td>$1.0M</td>
<td>15.7K</td>
<td>1.4K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.5</td>
<td>$14.4</td>
<td>$14.48</td>
<td>$185.00</td>
<td>$256.2K</td>
<td>15.7K</td>
<td>734</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$29.6</td>
<td>$28.95</td>
<td>$29.6</td>
<td>$165.00</td>
<td>$207.2K</td>
<td>2.4K</td>
<td>270</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$36.15</td>
<td>$35.8</td>
<td>$36.15</td>
<td>$175.00</td>
<td>$180.7K</td>
<td>662</td>
<td>125</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$35.25</td>
<td>$35.0</td>
<td>$35.0</td>
<td>$175.00</td>
<td>$175.0K</td>
<td>662</td>
<td>75</td>
</tr>
</tbody>
</table>

<h3>About Taiwan Semiconductor</h3>
Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with over 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the us in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.
Following our analysis of the options activities associated with Taiwan Semiconductor, we pivot to a closer look at the company's own performance.
<h3>Where Is Taiwan Semiconductor Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,767,619, the price of TSM is up by 4.72%, reaching $193.38.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 45 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Taiwan Semiconductor</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $240.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Taiwan Semiconductor, which currently sits at a price target of $240. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Taiwan Semiconductor options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Taiwan Semiconductor's Options Frenzy: What You Need to Know

High-rolling investors have positioned themselves bearish on Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SNOW often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 16 options trades for Snowflake. This is not a typical pattern.
The sentiment among these major traders is split, with 37% bullish and 43% bearish. Among all the options we identified, there was one put, amounting to $242,570, and 15 calls, totaling $4,976,474.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $210.0 for Snowflake, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Snowflake's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Snowflake's whale activity within a strike price range from $85.0 to $210.0 in the last 30 days. 
<h3>Snowflake Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733155225_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$36.6</td>
<td>$32.5</td>
<td>$32.55</td>
<td>$165.00</td>
<td>$3.3M</td>
<td>1.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.25</td>
<td>$8.0</td>
<td>$8.01</td>
<td>$210.00</td>
<td>$881.1K</td>
<td>2.0K</td>
<td>12</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.64</td>
<td>$2.54</td>
<td>$2.54</td>
<td>$150.00</td>
<td>$242.5K</td>
<td>830</td>
<td>956</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$2.13</td>
<td>$2.02</td>
<td>$2.13</td>
<td>$177.50</td>
<td>$105.6K</td>
<td>2.6K</td>
<td>997</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.85</td>
<td>$9.6</td>
<td>$9.6</td>
<td>$170.00</td>
<td>$96.0K</td>
<td>1.8K</td>
<td>100</td>
</tr>
</tbody>
</table>

<h3>About Snowflake</h3>
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that went public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to buy and ingest data, while its data solutions can be hosted on various public clouds.
<h3>Current Position of Snowflake</h3>
<ul>
<li>With a volume of 1,585,748, the price of SNOW is up 0.59% at $175.84. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 86 days.</li>
</ul>
<h3>What Analysts Are Saying About Snowflake</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $175.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Snowflake, which currently sits at a price target of $150. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Snowflake, which currently sits at a price target of $180. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Snowflake, which currently sits at a price target of $190. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Snowflake with a target price of $172. 
&#x2A; An analyst from B of A Securities persists with their Neutral rating on Snowflake, maintaining a target price of $185. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Snowflake options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

SNOW

A Closer Look at Snowflake's Options Market Dynamics

In the latest quarter, 32 analysts provided ratings for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">18</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">9</td>
<td align="right">16</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $1022.41, a high estimate of $1250.00, and a low estimate of $900.00. Marking an increase of 10.48%, the current average surpasses the previous average price target of $925.44. 
<img src="https://www.benzinga.com/files/images/story/2024/1733155223_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of ServiceNow by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$1250.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$1150.00</td>
<td>$1075.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1070.00</td>
<td>$980.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1150.00</td>
<td>$1050.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$1071.00</td>
<td>$1068.00</td>
</tr>
<tr>
<td>Peter Weed</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$913.00</td>
<td>$906.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1045.00</td>
<td>$985.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$1025.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$990.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Jason Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1040.00</td>
<td>$1020.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1050.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$980.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$950.00</td>
<td>$820.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$975.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$1000.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$1075.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$900.00</td>
<td>$780.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$960.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$1000.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$1068.00</td>
<td>$915.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1020.00</td>
<td>$825.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$980.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$1000.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$1100.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$980.00</td>
<td>$890.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1025.00</td>
<td>$860.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$950.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$1055.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1025.00</td>
<td>$935.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$900.00</td>
<td>$900.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ServiceNow. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ServiceNow compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of ServiceNow's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into ServiceNow's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NOW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ServiceNow analyst ratings.</a>
<h2>Discovering ServiceNow: A Closer Look</h2>
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
<h3>Financial Insights: ServiceNow</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: ServiceNow's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 22.25%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: ServiceNow's net margin is impressive, surpassing industry averages. With a net margin of 15.45%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ServiceNow's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.81%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ServiceNow's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.36% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: ServiceNow's debt-to-equity ratio is below the industry average. With a ratio of 0.24, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On ServiceNow Through 32 Analysts

Investors with a lot of money to spend have taken a bearish stance on FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with FDX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for FedEx.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $391,323, and 3 are calls, for a total amount of $90,125.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $307.5 for FedEx, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for FedEx options trades today is 312.0 with a total volume of 864.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for FedEx's big money trades within a strike price range of $200.0 to $307.5 over the last 30 days.
<h3>FedEx Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733155219_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$15.55</td>
<td>$13.5</td>
<td>$15.05</td>
<td>$307.50</td>
<td>$167.0K</td>
<td align="right">2</td>
<td align="right">300</td>
</tr>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/13/24</td>
<td>$13.75</td>
<td>$13.0</td>
<td>$13.75</td>
<td>$307.50</td>
<td>$68.7K</td>
<td align="right">2</td>
<td align="right">200</td>
</tr>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$2.91</td>
<td>$2.13</td>
<td>$2.43</td>
<td>$295.00</td>
<td>$56.8K</td>
<td align="right">280</td>
<td align="right">240</td>
</tr>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$8.55</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$307.50</td>
<td>$54.4K</td>
<td align="right">53</td>
<td align="right">69</td>
</tr>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.95</td>
<td>$8.4</td>
<td>$8.88</td>
<td>$290.00</td>
<td>$44.2K</td>
<td align="right">926</td>
<td align="right">50</td>
</tr>
</tbody>
</table>

<h3>About FedEx</h3>
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2024, which ended in May, FedEx derived 47% of revenue from its express division, 37% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
<h3>Present Market Standing of FedEx</h3>
<ul>
<li>Currently trading with a volume of 275,433, the FDX's price is down by -2.18%, now at $296.06. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 17 days.</li>
</ul>
<h3>What The Experts Say On FedEx</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $348.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on FedEx with a target price of $365. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for FedEx, targeting a price of $331. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for FedEx with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of FedEx's Latest Options Trends

The U.S. manufacturing sector showed signs of improvement in November, yet it failed to avoid another <a href="https://www.benzinga.com/news/econ-s">month of contractionary conditions.</a>
The Manufacturing Purchasing Managers&#8217; Index (PMI) rose from October&#8217;s 46.5% to 48.4% in November, exceeding analyst expectations of 47.5%, as tracked by TradingEconomics.
<h3 class="wp-block-heading">November&#8217;s ISM Manufacturing PMI: Key Highlights</h3>
Despite the improvement, the PMI data released Monday by the Institute for Supply Management (ISM) remains below the 50% threshold, signaling contraction in the manufacturing sector for the eighth consecutive month.
The outcome marks the slowest contraction in the manufacturing sector since June.
The manufacturing sector has contracted in 24 of the last 25 months. In contrast, the broader U.S. economy, supported by services, has continued to expand for the 55th month in a row.
Key components of the PMI reflected varying degrees of improvement:
<ul>
<li>New Orders: Returned to expansion territory for the first time in eight months, rising from 47.1 in October to 50.4.</li>
<li>Production: Improved slightly from 46.2 to 46.8 but remained in contraction.</li>
<li>Employment: Contracted less sharply, with the index climbing from 44.4 to 48.1. </li>
<li>Inventories: Rose from 42.6 to 48.1.</li>
<li>Prices: Declined, with the Prices Index dropping from 54.8 to 50.3, indicating reduced price pressures.</li>
<li>Supplier Deliveries: Improved, as the index fell from 52 to 48.7, suggesting faster delivery times.</li>
</ul>
"U.S. manufacturing activity contracted again in November, but at a slower rate compared to last month. Demand continues to be weak but may be moderating," Timothy Fiore, chair of the ISM Manufacturing Business Survey Committee, said.
Fiore highlighted positive developments in demand, noting the rebound in the New Orders Index and a moderate rise in the New Export Orders Index, which increased by 3.2 percentage points but remained in contraction. Challenges persist, as the Backlog of Orders Index dipped further into &#8220;strong contraction territory.&#8221;
"Production execution eased in November, consistent with demand sluggishness and weak backlogs," Fiore added. On the supply side, he observed improvements in lead times but cautioned about the reappearance of some product shortages.
<h3 class="wp-block-heading">Market Reactions</h3>
The U.S. dollar index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), surged 1% on Monday. The dollar&#8217;s rally was supported not only by the upbeat PMI report but also by growing political uncertainty in Europe, where France&#8217;s government faces a potential no-confidence vote due to budgetary pressures.
U.S. equities were mixed in early trading. The S&amp;P 500 – tracked by SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)  edged up 0.1%, while the Dow Jones Industrial Average slipped 0.4%. Tech stocks outperformed, driving the Nasdaq 100 – tracked by Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – up 1%.
In the bond market, U.S. Treasury yields rose modestly. The 10-year yield climbed by 5 basis points to 4.23%. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42265847/biden-targets-china-with-new-chip-restrictions-nvidia-slides">Biden Targets China With New Chip Restrictions, Nvidia Slides</a></li>
</ul>
Photo via Shutterstock.

Sector ETFs

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

US Manufacturing Output Tops Forecasts In November: Is The Sector's Crisis Over?

In the last three months, 6 analysts have published ratings on Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Nevro and provided 12-month price targets. The average target is $6.0, accompanied by a high estimate of $7.00 and a low estimate of $4.00. A decline of 16.08% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1733155211_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Nevro. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$4.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$6.89</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Nevro. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Nevro compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Nevro's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Nevro's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NVRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nevro analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Nevro</h2>
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
<h3>Unraveling the Financial Story of Nevro</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Nevro's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -6.69%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Nevro's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -15.83% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Nevro's ROE excels beyond industry benchmarks, reaching -5.6%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.56%, the company showcases effective utilization of assets.
Debt Management: Nevro's debt-to-equity ratio stands notably higher than the industry average, reaching 0.9. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVRO

What Analysts Are Saying About Nevro Stock

U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Monday.
Shares of XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) rose sharply <a href="https://www.benzinga.com/24/12/42260165/li-auto-xpeng-nio-heres-how-november-deliveries-of-chinese-ev-startups-stack-up">during Monday's session</a>.
The company delivered 30,895 vehicles last month, marking an increase of 54% year-over-year and 29% from October.
The Guangzhou-based EV startup said that the company&#8217;s deliveries of the XPeng Mona M03 hatchback coupe alone exceeded 10,000 units for the third consecutive month since launch. Deliveries of the XPeng P7+ sedan, which the company launched last month, also exceeded 7,000 units.
XPeng shares jumped 6.4% to $12.82 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) shares gained 29.9% to $26.04 after the company announced its Phase 3 PANOVA-Trial met its primary endpoint and demonstrated a statistically significant improvement in its median overall survival rate.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) surged 22% to $39.83 after the company announced it completed a review by an independent special committee and stated EY&#8217;s conclusions were not supported by findings.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) jumped 17% to $9.92.</li>
<li>Nebius Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>) shares gained 15.5% to $25.40 after the company announced it entered a $700 million private placement financing agreement with institutional investors.</li>
<li>Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) gained 15.1% to $10.65.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) jumped 14.6% to $24.41.</li>
<li>PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) surged 14.3% to $50.15 after the company announced it signed a global licensee and collaboration agreement with Novartis for its PTC518 Huntington&#8217;s Disease program.</li>
<li>Dana Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) gained 14% to $11.39 after Barclays upgraded the stock from Equal-Weight to Overweight and raised its price target from $12 to $18.</li>
<li>MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) gained 12.9% to $22.60. The company, on Friday, posted first-quarter results.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) climbed 11.3% to $7.87.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) rose 8.8% to $0.9000.</li>
<li>Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) gained 8.2% to $161.94.</li>
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) gained 8% to $48.43 after the company announced it entered into an agreement to exclusively license the right to Ptx the right to commercialize Zenocutuzumab (Zeno) for Nrg1 Fusion-positive cancer in the US.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) rose 5.7% to $25.63 after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $28 to $30.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42264122/wall-streets-most-accurate-analysts-give-their-take-on-3-financial-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields</a></li>
</ul>

Comments

Okuwa

Okuwa (OWWAF) Forecast

Okuwa (OTC:OWWAF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga